相关实验视频

Updated: May 29, 2025

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

人工智能在前列腺特异性膜抗原正子发射断层扫描中的价值:最新情况

Jianliang Liu¹, Kieran Sandhu², Dixon T S Woon³

¹EJ Whitten Prostate Cancer Research Centre, Epworth Healthcare, Melbourne, Australia; Department of Urology, The Royal Melbourne Hospital, University of Melbourne, Melbourne, Australia; University of Melbourne, Department of Surgery, Melbourne, Australia; Department of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Australia.

Seminars in nuclear medicine

|February 1, 2025

概括

人工智能 (AI) 在分析前列腺特异性膜抗原 (PSMA) PET扫描前列腺癌 (PCa) 方面表现有前途. 人工智能有助于检测转移,分类瘤,预测治疗反应,改善患者护理.

科学领域:

在瘤学瘤学.
放射学放射学是一门学科.
人工智能的人工智能

背景情况:

前列腺癌 (PCa) 管理依赖于准确的成像.
前列腺特异性膜抗原 (PSMA) 定子发射断层扫描 (PET) 扫描对于PCa分期和治疗监测至关重要.
评估PSMA PET扫描可能是复杂和耗时的.

研究的目的:

审查人工智能 (AI) 在分析PSMA PET扫描PCa.目前的实用性.
探索AI在自动化图像分析和提高诊断精度方面的作用.
在治疗反应预测和放射治疗规划中识别AI应用.

主要方法:

在主要的科学数据库 (Medline,Embase,Web of Science,IEEE Xplore) 进行了全面的文献审查.
包括专注于人工智能应用在前列腺癌中PSMA PET扫描评估的研究.
排除包括案例报告,评论和会议记录;只考虑到2024年10月的原始英语研究.

主要成果:

人工智能在PSMA PET扫描上自动检测转移性疾病和解剖细分方面的潜力显著.
人工智能可以预测对基于PSMA的治疗诊断的反应,并协助用于放射治疗计划的瘤负担细分.
人工智能显示在区分高度的前列腺内PCa和预测前列腺外延伸方面有能力.

结论:

人工智能对提高PSMA PET扫描在前列腺癌检测和管理中的评估具有相当大的前景.
人工智能应用对于转移检测,瘤负担评估和预测治疗结果特别有价值.
进一步的大规模,多中心的前性研究对于验证人工智能模型和确保其广泛的临床适用性至关重要.

更多相关视频

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound

Published on: March 21, 2025

Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy

Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy

Published on: April 9, 2019

相关概念视频

Positron Emission Tomography

Positron Emission Tomography

Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...

Imaging Studies II: Positron Emission Tomography and Scintigraphy

Imaging Studies II: Positron Emission Tomography and Scintigraphy

Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET